Nonetheless, due to varying levels of 4E-BPs versus eIF4E in cancer tissues, our results propose an important determinant by which HCC tumors may be inherently resistant, or develop resistance, to metformin through downregulation of 4E-BPs. The gene discussed is EIF4E; the disease is hepatocellular carcinoma.